Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 6/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505292 | 1.00 | HRH3 (0.47) | HRH3IRAK1IRAK4NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL29505368 | 0.99 | HRH3 (0.46) | HRH3IRAK1IRAK4NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL16896479 | 0.99 | HRH3 (0.46) | HRH3IRAK1IRAK4NPC1RAB9A | |
| SCHEMBL28375412 | 0.90 | HRH3 (0.44) | HRH3IRAK1IRAK4NPC1RAB9A | |
| SCHEMBL16896433 | 0.90 | HRH3 (0.47) | HRH3IRAK1IRAK4NPC1RAB9A | |
| SCHEMBL22769537 | 0.86 | HRH3 (0.43) | HRH3IRAK1IRAK4NPC1RAB9A | |
| SCHEMBL22769539 | 0.86 | HRH3 (0.43) | HRH3IRAK1IRAK4KCNH2HTT | |
| SCHEMBL30461092 | 0.86 | HRH3 (0.43) | HRH3IRAK1IRAK4KCNH2HTT | |
| SCHEMBL16896364 | 0.84 | PLAU (0.45) | HRH3 | |
| SCHEMBL29505200 | 0.84 | PLAU (0.45) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414582-A1 | METHODS OF TREATING DISEASES AND DISORDERS | CURIS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4252853-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Oncology Limited (IN) | 2023-10-04 | — | — | EP | claimed |
| EP-4248212-A1 | METHODS OF TREATING DISEASES AND DISORDERS | Curis, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116710776-A | Methods of treating diseases and disorders | 柯里斯公司 | 2023-09-05 | — | — | CN | claimed |
| EP-3600270-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE ONCOLOGY LTD (IN) | 2023-06-14 | — | — | EP | claimed |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | claimed |
| WO-2022108996-A1 | METHODS OF TREATING DISEASES AND DISORDERS | CURIS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-111362966-B | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-09-23 | — | — | US | claimed |
| EP-3466955-B1 | METHOD OF PREPARING OXAZOLO[4,5-B]PYRIDINE AND THIAZOLO[4,5-B]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS FOR TREATING CANCER | AURIGENE DISCOVERY TECH LTD (IN) | 2020-12-16 | — | — | EP | claimed |
| CN-106456619-B | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2020-03-27 | — | — | CN | claimed |
| EP-3600270-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Discovery Technologies Limited (IN) | 2020-02-05 | — | — | EP | claimed |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2019-05-09 | — | — | US | claimed |
| EP-3466955-A1 | METHOD OF PREPARING OXAZOLO[4,5-B]PYRIDINE AND THIAZOLO[4,5-B]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS FOR TREATING CANCER | Aurigene Discovery Technologies Limited (IN) | 2019-04-10 | — | — | EP | claimed |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| WO-2018178947-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-10-04 | — | — | WO | claimed |
| EP-3094329-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2018-09-26 | — | — | EP | claimed |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | claimed |
| US-9732095-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-15 | — | — | US | claimed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414582-A1 | METHODS OF TREATING DISEASES AND DISORDERS | IRAK4, IRAK3, IRAK2 | HRH3 2770/4885IRAK1 4/4885IRAK4 1/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | HRH3 2239/4885IRAK1 2/4885IRAK4 1/4885 |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | HRH3 2293/4885IRAK1 3/4885IRAK4 1/4885 |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, FLT3, IRAK3 | HRH3 1892/4885IRAK1 6/4885IRAK4 1/4885 |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | HRH3 2293/4885IRAK1 3/4885IRAK4 1/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | HRH3 1892/4885IRAK1 6/4885IRAK4 1/4885 |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | HRH3 2417/4885IRAK1 6/4885IRAK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.